

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC2016/0005101				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
PALABRAS CLAVE UTILIZADAS		Cd127 antibody, IL7R antibody, anti-cd27, anti-IL7R.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07K16/28		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	NA			
ISA/IPEA (EPO) EPO Epoquenet (epodoc)	WO2011/094259	4/08/2011	NA	A
ISA/IPEA (EPO) EPO	WO2013/056984	25/04/2013	NA	A
	WO2011/104687	1/09/2011	NA	A
NCBI(SEQ 22, 24, 36, 38, 40, 42, 44, 46)	NA			
LENS (FINDER)	NA			
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.	
---	--

Fecha del reporte de búsqueda:	11/03/2018
--------------------------------	------------

CLUSTAL O(1.2.4) multiple sequence alignment

```

WO2015189302_22      AVQLVESGGGLVQPGGSLKLSCAVSGFTLSDYYMAWVRQAPKKGLEWVATISASGLRITY
WO2015189302_36      QVQLVESGGGLVKPGGSLRLSCAVSGFTLSDYYMAWVRQAPKKGLEWVATISASGLRITY
WO2015189302_38      QVQLVESGGGLVKPGGSLRLSCAVSGFTLSDYYMAWIRQAPKKGLEWVSTISASGLRITY
WO2015189302_40      QVQLVESGGGLVKPGGSLRLSCAVSGFTLSDYYMAWIRQAPKKGLEWVSTISASGLRITY
                        *****
WO2015189302_22      PDSVKGRFTISRDDAKRSLFLQMTSLKSEDTATYYCARPMSAHYGFNYFD-----
WO2015189302_36      PDSVKGRFTISRDAKNSLYLQMNSLRAEDTAVYYCARPMSAHYGFNYFDYWGQGLVTV
WO2015189302_38      PDSVKGRFTISRDAKNSLYLQMNSLRAEDTAVYYCARPMSAHYGFNYFDYWGQGLVTV
WO2015189302_40      PDSVKGRFTISRDAKNSLYLQMNSLRAEDTAVYYCARPLSAHYGFNYFDYWGQGLVTV
                        *****
WO2015189302_22      --
WO2015189302_36      SS
WO2015189302_38      SS
WO2015189302_40      SS

```

CLUSTAL O(1.2.4) multiple sequence alignment

```

WO2015189302_24      DIQMTQSPASLSASLGTVTIECRTSEDIYNGLAWYQQKPGKSPQLLVYSANSLHIGVPS
WO2015189302_42      EIVMTQSPATLSVSPGERATLSCRTSEDIYNGLAWYQQKPGQAPRLLVYSANSLHIGIPA
WO2015189302_44      EIVMTQSPATLSVSPGERATLSCRTSEDIYNGLAWYQQKPGQAPRLLIYSANSLHIGIPA
WO2015189302_46      EIVMTQSPATLSVSPGERATLSCRTSEDIYQGLAWYQQKPGQAPRLLIYSANTLHIGIPA
                        .*
WO2015189302_24      RFGSGSGGTQYSLKINSLQFEDVASYFCQQYYDYPLAFGSGTKLEIKR-----
WO2015189302_42      RFGSGSGGTEYTLTISSLQSEDFAVYFCQQYYDYPLAFGGGKVEIK-----
WO2015189302_44      RFGSGSGGTEFTLTISLQSEDFAVYYCQQYYDYPLAFGGGKVEIK-----
WO2015189302_46      RFGSGSGGTEFTLTISLQSEDFAVYYCQQYYDYPLAFGGGKVEIKYWGQVMVTVSS
                        *****

```

Base de datos	NCBI- PATENTED SEQUENCES
QUERY	SEQ. 22, 24, 36, 38, 40, 42, 46
ENTREZ TERM	CD127 OR IL7R

QUERY	SUBJECT	%id
WO2015189302_22	AKW35997.1	76.8
WO2015189302_22	AKW35997.1	68.103
WO2015189302_22	AKW35991.1	76
WO2015189302_22	AKW35991.1	67.241
WO2015189302_22	AKW35987.1	76
WO2015189302_22	AKW35987.1	67.241
WO2015189302_22	AKW35989.1	75.2
WO2015189302_22	AKW35989.1	66.379
WO2015189302_22	AKW35996.1	75.2
WO2015189302_22	AKW35996.1	66.379
WO2015189302_22	AKW35993.1	76
WO2015189302_22	AKW35993.1	67.241
WO2015189302_22	AKW35990.1	75.2
WO2015189302_22	AKW35990.1	66.379
WO2015189302_22	AKW35988.1	75.2
WO2015189302_22	AKW35988.1	66.379
WO2015189302_22	AKW35998.1	75.2
WO2015189302_22	AKW35998.1	66.379
WO2015189302_22	AKW35994.1	75.2
WO2015189302_22	AKW35994.1	66.379
WO2015189302_38	AKW35997.1	76
WO2015189302_38	AKW35991.1	75.2
WO2015189302_38	AKW35987.1	75.2
WO2015189302_38	AKW35994.1	75.2
WO2015189302_38	AKW35989.1	74.4
WO2015189302_38	AKW35996.1	74.4
WO2015189302_38	AKW35990.1	74.4
WO2015189302_38	AKW35988.1	74.4
WO2015189302_38	AKW35998.1	74.4
WO2015189302_38	AKW35993.1	74.4
WO2015189302_40	AKW35997.1	76
WO2015189302_40	AKW35991.1	75.2
WO2015189302_40	AKW35987.1	75.2
WO2015189302_40	AKW35994.1	75.2
WO2015189302_40	AKW35989.1	74.4
WO2015189302_40	AKW35996.1	74.4
WO2015189302_40	AKW35990.1	74.4
WO2015189302_40	AKW35988.1	74.4
WO2015189302_40	AKW35998.1	74.4
WO2015189302_40	AKW35993.1	74.4

WO2015189302_42	AKW35959.1	73.148
WO2015189302_42	AKW35957.1	72.222
WO2015189302_42	AKW35960.1	72.222
WO2015189302_42	AKW35958.1	71.296
WO2015189302_42	AKW35961.1	71.296
WO2015189302_42	AKW35962.1	71.296
WO2015189302_42	AKW35963.1	70.37
WO2015189302_42	AKW36006.1	71.296
WO2015189302_42	AKW35964.1	69.444
WO2015189302_42	AKW36008.1	76.087
WO2015189302_44	AKW35957.1	75
WO2015189302_44	AKW35959.1	74.074
WO2015189302_44	AKW35958.1	74.074
WO2015189302_44	AKW35961.1	74.074
WO2015189302_44	AKW35960.1	73.148
WO2015189302_44	AKW36006.1	74.074
WO2015189302_44	AKW35962.1	72.222
WO2015189302_44	AKW36008.1	79.348
WO2015189302_44	AKW35963.1	71.296
WO2015189302_44	AKW35964.1	70.37
WO2015189302_46	AKW35957.1	75
WO2015189302_46	AKW35959.1	74.074
WO2015189302_46	AKW35958.1	74.074
WO2015189302_46	AKW35961.1	74.074
WO2015189302_46	AKW35960.1	73.148
WO2015189302_46	AKW36006.1	74.074
WO2015189302_46	AKW36008.1	78.723
WO2015189302_46	AKW35962.1	72.222
WO2015189302_46	AKW35963.1	71.296
WO2015189302_46	AKW35964.1	70.37
WO2015189302_24	AKW35976.1	70.642
WO2015189302_24	AKW36000.1	66.972
WO2015189302_24	AKW36002.1	66.972
WO2015189302_24	AKW36022.1	65.138
WO2015189302_24	AKW35999.1	66.055
WO2015189302_24	AKW36001.1	66.055
WO2015189302_24	AKW35959.1	54.63
WO2015189302_24	AKW35957.1	53.704
WO2015189302_24	AKW35948.1	55.556
WO2015189302_24	AKW35960.1	53.704

Base de datos	EPODOC
---------------	--------

[EPODOC: SS 1] cd127 OR il7r

Results in EPODOC 93

[SS 2] 1 and antibody

Results in EPODOC 5

[SS 3] 2 and pd<20140610

Results in EPODOC 2


[SS 4] ..li pd/pn/ti/ab



1/2	© EPODOC / EPO
PD	- 2014-02-25
PN	- UA104663 C2 20140225
TI	- ANTIBODY BINDING TO CD127
AB	- The invention relates to antigen-binding protein binding to human IL-7 receptor (CD127) and can be used in the treatment of the diseases or pathologic states, especially autoimmune or inflammatory diseases.

2/2	© EPODOC / EPO
PD	- 2012-09-28
PN	- NZ590994 A 20120928
TI	- ANTI IL-7R ANTIBODIES TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASE
AB	- Disclosed is the use of an anti- CD127 antibody in the manufacture of a medicament for use in the treatment of multiple sclerosis in a human subject, wherein said anti- CD127 antibody is an antagonist of IL-7 receptor mediated TH17 expansion and survival.

Figure 11C



base de datos	LENS-FINDER			
QUERY	SEQ: 22			
Patent Number	Title	Publication Date	SEQ ID NO	Local % Id
WO 1999 022008 A1	INDUCER FOR PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING GENE THEREFOR, AND METHOD OF INDUCING PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY	06/05/99	11	81.%
US 2010 0173324 A1	ANTI-CD27 ANTIBODY	08/07/10	28	74.6%
US 2012 0093805 A1	ANTI-CD27 HUMANIZED MONOCLONAL ANTIBODY	19/04/12	28	74.6%
WO 2010 001908 A1	ANTI-CD27 ANTIBODY	07/01/10	65	74.6%
WO 2011 081164 A1	ANTI-CD27 ANTIBODY	07/07/11	65	74.6%
EP 2314628 A1	ANTI-CD27 ANTIBODY	27/04/11	28	74.6%
EP 2520589 A1	ANTI-CD27 ANTIBODY	07/11/12	28	74.6%
CA 2729567 A1	ANTI-CD27 ANTIBODY	07/01/10	28	74.6%
CA 2785964 A1	ANTI-CD27 ANTIBODY	07/07/11	28	74.6%
US 2004 0058394 A1	Humanized anti-LT-beta-R antibodies	25/03/04	14	77.7%
US 2009 0092601 A1	HUMANIZED ANTI-LT-beta-R ANTIBODIES	09/04/09	14	77.7%
US 7429644 B2	Humanized anti-LT-beta-R antibodies	30/09/08	14	77.7%
JP 2004532608 A		28/10/04	30	77.7%
WO 2002 030986 A2	HUMANIZED ANTI-LT- beta -R ANTIBODIES	18/04/02	14	77.7%
KR 20030041164 A		23/05/03	14	77.7%
CA 2425809 A1	HUMANIZED ANTI-LT-.BETA.-R ANTIBODIES	18/04/02	14	77.7%
US 2013 0052197 A1	NOVEL ANTI-CD98 ANTIBODY AND USE THEREOF	28/02/13	2	79.3%
WO 2011 118804 A1	NOVEL ANTI-CD98 ANTIBODY AND USE THEREOF	29/09/11	9	79.3%
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	141	76.%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	141	76.%
JP 2008541758 A		27/11/08	141	76.%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	141	76.%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	141	76.%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1566	75.2%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	1910	75.2%
JP 2012508016 A		05/04/12	2573	75.2%
JP 2013510164 A		21/03/13	1917	75.2%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1566	75.2%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	1910	75.2%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1566	75.2%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	1910	75.2%
US 2004 0058394 A1	Humanized anti-LT-beta-R antibodies	25/03/04	16	76.9%
US 2009 0092601 A1	HUMANIZED ANTI-LT-beta-R ANTIBODIES	09/04/09	16	76.9%
US 7429644 B2	Humanized anti-LT-beta-R antibodies	30/09/08	16	76.9%
JP 2004532608 A		28/10/04	31	76.9%
WO 2002 030986 A2	HUMANIZED ANTI-LT- beta -R ANTIBODIES	18/04/02	16	76.9%
WO 2008 020827 A2	ALTERED POLYPEPTIDES, IMMUNOCONJUGATES THEREOF, AND METHODS RELATED THERETO	21/02/08	11	76.9%
KR 20030041164 A		23/05/03	16	76.9%
CA 2425809 A1	HUMANIZED ANTI-LT-.BETA.-R ANTIBODIES	18/04/02	16	76.9%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1571	75.2%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	1915	75.2%
JP 2012508016 A		05/04/12	2578	75.2%
JP 2013510164 A		21/03/13	1922	75.2%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1571	75.2%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	1915	75.2%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1571	75.2%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	1915	75.2%
US 2010 0260754 A1	DKK-1 ANTIBODIES	14/10/10	51	76.9%
US 8148498 B2	DKK-1 antibodies	03/04/12	51	76.9%
JP 2012523417 A		04/10/12	51	76.9%
WO 2010 117980 A1	DKK-1 ANTIBODIES	14/10/10	51	76.9%
KR 20110124364 A	DKK-1 ANTIBODIES	16/11/11	51	76.9%
US 2010 0260754 A1	DKK-1 ANTIBODIES	14/10/10	12	76.9%
US 8148498 B2	DKK-1 antibodies	03/04/12	12	76.9%
JP 2012523417 A		04/10/12	18	76.9%
WO 2010 117980 A1	DKK-1 ANTIBODIES	14/10/10	12	76.9%
KR 20110124364 A	DKK-1 ANTIBODIES	16/11/11	12	76.9%
US 2010 0260754 A1	DKK-1 ANTIBODIES	14/10/10	11	76.9%
US 8148498 B2	DKK-1 antibodies	03/04/12	11	76.9%
JP 2012523417 A		04/10/12	17	76.9%
WO 2010 117980 A1	DKK-1 ANTIBODIES	14/10/10	11	76.9%
KR 20110124364 A	DKK-1 ANTIBODIES	16/11/11	11	76.9%
US 2012 0034228 A1	CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY	09/02/12	2057	74.4%
US 2007 0243194 A1	Anti-IGF-1R antibodies and uses thereof	18/10/07	20	74.4%
US 2009 0092614 A1	Anti-IGF-1R Antibodies and Uses Thereof	09/04/09	20	74.4%
US 2009 0130105 A1	COMPOSITIONS THAT BIND MULTIPLE EPITOPES OF IGF-1R	21/05/09	20	74.4%

US 2009 0291088 A1	THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS	26/11/09	20	74.4%
US 2010 0098710 A1	Anti-IGF-1R Antibodies and Uses Thereof	22/04/10	20	74.4%
US 2010 0099147 A1	Anti-IGF-1R Antibodies and Uses Thereof	22/04/10	20	74.4%
US 7612178 B2	Anti-IGF-1R antibodies and uses thereof	03/11/09	20	74.4%
US 8147829 B2	Anti-IGF-1R antibodies and uses thereof	03/04/12	20	74.4%
JP 2009532027 A		10/09/09	62	74.4%
JP 2010537985 A		09/12/10	62	74.4%
JP 2010538012 A		09/12/10	88	74.4%
JP 2012504402 A		23/02/12	2104	74.4%
JP 2011516549 A		26/05/11	62	74.4%
WO 2009 032782 A2	COMPOSITIONS THAT BIND MULTIPLE EPITOPES OF IGF-1R	12/03/09	20	74.4%
EP 2190480 A1	ANTI-IGF-1R ANTIBODIES AND USES THEREOF	02/06/10	20	74.4%
EP 2274010 A1	THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS	19/01/11	20	74.4%
WO 2009 126304 A1	THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS	15/10/09	20	74.4%
CA 2646406 A1	ANTI-IGF-1R ANTIBODIES AND USES THEREOF	08/11/07	20	74.4%
CA 2697612 A1	ANTI-IGF-1R ANTIBODIES AND USES THEREOF	12/03/09	20	74.4%
CA 2697922 A1	COMPOSITIONS THAT BIND MULTIPLE EPITOPES OF IGF-1R	12/03/09	20	74.4%
CA 2738545 A1	CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY	08/04/10	2057	74.4%
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	86	74.8%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	86	74.8%
JP 2008541758 A		27/11/08	113	74.8%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	86	74.8%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	86	74.8%
US 2004 0058394 A1	Humanized anti-LT-beta-R antibodies	25/03/04	12	76%
US 2009 0092601 A1	HUMANIZED ANTI-LT-beta-R ANTIBODIES	09/04/09	12	76%
US 7429644 B2	Humanized anti-LT-beta-R antibodies	30/09/08	12	76%
JP 2004532608 A		28/10/04	29	76%
WO 2002 030986 A2	HUMANIZED ANTI-LT- beta -R ANTIBODIES	18/04/02	12	76%
KR 20030041164 A		23/05/03	12	76%
CA 2425809 A1	HUMANIZED ANTI-LT-.BETA.-R ANTIBODIES	18/04/02	12	76%
US 2010 0173324 A1	ANTI-CD27 ANTIBODY	08/07/10	107	72.1%
US 2012 0093805 A1	ANTI-CD27 HUMANIZED MONOCLONAL ANTIBODY	19/04/12	107	72.1%
WO 2010 001908 A1	ANTI-CD27 ANTIBODY	07/01/10	107	72.1%
WO 2011 081164 A1	ANTI-CD27 ANTIBODY	07/07/11	107	72.1%
EP 2314628 A1	ANTI-CD27 ANTIBODY	27/04/11	107	72.1%
EP 2520589 A1	ANTI-CD27 ANTIBODY	07/11/12	107	72.1%
CA 2729567 A1	ANTI-CD27 ANTIBODY	07/01/10	107	72.1%
CA 2785964 A1	ANTI-CD27 ANTIBODY	07/07/11	107	72.1%
US 2012 0225013 A1	ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES	06/09/12	15	75.2%
JP 2014509835 A		24/04/14	15	75.2%
WO 2012 087962 A2	ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES	28/06/12	15	75.2%
WO 2013 025834 A2	COMPOSITIONS AND METHODS RELATED TO ANTIBODIES TO STAPHYLOCOCCAL PROTEIN A	21/02/13	94	76%
CA 2845259 A1	COMPOSITIONS AND METHODS RELATED TO ANTIBODIES TO STAPHYLOCOCCAL PROTEIN A	21/02/13	94	76%
US 2009 0175881 A1	ANTIBODIES TO IL-17A	09/07/09	33	76.9%
US 2011 0038878 A1	ANTIBODIES TO IL-17A	17/02/11	33	76.9%
US 2011 0052596 A1	ANTIBODIES TO IL-17A	03/03/11	33	76.9%
US 7846443 B2	Antibodies to IL-17A	07/12/10	33	76.9%
US 8193319 B2	Antibodies to IL-17A	05/06/12	33	76.9%
JP 2010500028 A		07/01/10	37	76.9%
WO 2008 021156 A2	ANTIBODIES TO IL-17A	21/02/08	33	76.9%
JP 2013009680 A	ANTIBODY TO IL-17A	17/01/13	37	76.9%
KR 101218484 B1	ANTIBODIES TO IL-17A	04/01/13	33	76.9%
CA 2660463 C	ANTIBODIES TO IL-17A	16/07/13	33	76.9%
US 2004 0058394 A1	Humanized anti-LT-beta-R antibodies	25/03/04	2	76%
US 2009 0092601 A1	HUMANIZED ANTI-LT-beta-R ANTIBODIES	09/04/09	2	76%
US 7429644 B2	Humanized anti-LT-beta-R antibodies	30/09/08	2	76%
JP 2004532608 A		28/10/04	24	76%
WO 2002 030986 A2	HUMANIZED ANTI-LT- beta -R ANTIBODIES	18/04/02	2	76%
WO 2008 020827 A2	ALTERED POLYPEPTIDES, IMMUNOCONJUGATES THEREOF, AND METHODS RELATED THERETO	21/02/08	9	76%
KR 20030041164 A		23/05/03	2	76%
CA 2425809 A1	HUMANIZED ANTI-LT-.BETA.-R ANTIBODIES	18/04/02	2	76%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1574	73.6%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	1918	73.6%
JP 2012508016 A		05/04/12	2581	73.6%
JP 2013510164 A		21/03/13	1925	73.6%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1574	73.6%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	1918	73.6%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1574	73.6%

CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	1918	73.6%
US 2010 0173324 A1	ANTI-CD27 ANTIBODY	08/07/10	96	72.1%
US 2012 0093805 A1	ANTI-CD27 HUMANIZED MONOCLONAL ANTIBODY	19/04/12	96	72.1%
WO 2010 001908 A1	ANTI-CD27 ANTIBODY	07/01/10	102	72.1%
WO 2011 081164 A1	ANTI-CD27 ANTIBODY	07/07/11	102	72.1%
EP 2314628 A1	ANTI-CD27 ANTIBODY	27/04/11	96	72.1%
EP 2520589 A1	ANTI-CD27 ANTIBODY	07/11/12	96	72.1%
CA 2729567 A1	ANTI-CD27 ANTIBODY	07/01/10	96	72.1%
CA 2785964 A1	ANTI-CD27 ANTIBODY	07/07/11	96	72.1%
US 2013 0251733 A1	ANTI-CXCR3 ANTIBODIES	26/09/13	31	73.2%
CA 2862222 A1	ANTI-CXCR3 ANTIBODIES	25/07/13	31	73.2%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1710	73.6%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	2054	73.6%
JP 2012508016 A		05/04/12	2717	73.6%
JP 2013510164 A		21/03/13	2061	73.6%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1710	73.6%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2054	73.6%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1710	73.6%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2054	73.6%
US 2010 0254975 A1	ALPHA-4 BETA-7 HETERODIMER SPECIFIC	07/10/10	36	75.2%
US 2012 0183561 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	19/07/12	36	75.2%
US 2012 0177662 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	12/07/12	36	75.2%
US 2013 0302354 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	14/11/13	36	75.2%
US 8444981 B2	Alpha-4 beta-7 heterodimer specific antagonist antibody	21/05/13	36	75.2%
US 8454961 B2	Alpha-4-beta-7 heterodimer specific antagonist antibody	04/06/13	36	75.2%
US 8454962 B2	Alpha-4-beta-7 heterodimer specific antagonist antibody	04/06/13	36	75.2%
JP 2012520679 A		10/09/12	44	75.2%
WO 2010 107752 A2	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	23/09/10	36	75.2%
KR 101391472 B1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	07/05/14	36	75.2%
CA 2851737 A1	ALPHA-4BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	23/09/10	36	75.2%
US 2011 0256154 A1	ANTI-ERBB3 ANTIBODIES	20/10/11	150	76%
US 2013 0330772 A1	ANTI-ERBB3 ANTIBODIES	12/12/13	150	76%
US 8481687 B2	Anti-ErbB3 antibodies	09/07/13	150	76%
JP 2013523166 A		17/06/13	181	76%
WO 2011 136911 A2	ANTI-ERBB3 ANTIBODIES	03/11/11	150	76%
WO 2014 011489 A2	MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOMIMMUNE DISEASE	16/01/14	16	75.6%
CA 2883056 A1	MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOMIMMUNE DISEASE	16/01/14	16	75.6%
US 2010 0254975 A1	ALPHA-4 BETA-7 HETERODIMER SPECIFIC	07/10/10	42	75.2%
US 2012 0183561 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	19/07/12	42	75.2%
US 2012 0177662 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	12/07/12	42	75.2%
US 2013 0302354 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	14/11/13	42	75.2%
US 8444981 B2	Alpha-4 beta-7 heterodimer specific antagonist antibody	21/05/13	42	75.2%
US 8454961 B2	Alpha-4-beta-7 heterodimer specific antagonist antibody	04/06/13	42	75.2%
US 8454962 B2	Alpha-4-beta-7 heterodimer specific antagonist antibody	04/06/13	42	75.2%
JP 2012520679 A		10/09/12	50	75.2%
WO 2010 107752 A2	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	23/09/10	42	75.2%
KR 101391472 B1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	07/05/14	42	75.2%
CA 2851737 A1	ALPHA-4BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	23/09/10	42	75.2%
US 2011 0076284 A1	Novel Modulators	31/03/11	175	74.4%
JP 2013505953 A		21/02/13	175	74.4%
WO 2011 038302 A2	NOVEL MODULATORS	31/03/11	175	74.4%
KR 20140015135 A	INSULIN RECEPTOR BINDING ANTIBODIES	06/02/14	175	74.4%
CA 2773099 A1	NOVEL MODULATORS	31/03/11	175	74.4%
WO 2008 020827 A2	ALTERED POLYPEPTIDES, IMMUNOCONJUGATES THEREOF, AND METHODS RELATED THERETO	21/02/08	24	76.9%
US 2010 0173324 A1	ANTI-CD27 ANTIBODY	08/07/10	103	71.3%
US 2012 0093805 A1	ANTI-CD27 HUMANIZED MONOCLONAL ANTIBODY	19/04/12	103	71.3%
WO 2010 001908 A1	ANTI-CD27 ANTIBODY	07/01/10	105	71.3%
WO 2011 081164 A1	ANTI-CD27 ANTIBODY	07/07/11	105	71.3%
EP 2314628 A1	ANTI-CD27 ANTIBODY	27/04/11	103	71.3%
EP 2520589 A1	ANTI-CD27 ANTIBODY	07/11/12	103	71.3%
CA 2729567 A1	ANTI-CD27 ANTIBODY	07/01/10	103	71.3%
CA 2785964 A1	ANTI-CD27 ANTIBODY	07/07/11	103	71.3%
US 2004 0058394 A1	Humanized anti-LT-beta-R antibodies	25/03/04	10	75.2%
US 2009 0092601 A1	HUMANIZED ANTI-LT-beta-R ANTIBODIES	09/04/09	10	75.2%
US 7429644 B2	Humanized anti-LT-beta-R antibodies	30/09/08	10	75.2%
JP 2004532608 A		28/10/04	28	75.2%
WO 2002 030986 A2	HUMANIZED ANTI-LT- beta -R ANTIBODIES	18/04/02	10	75.2%
KR 20030041164 A		23/05/03	10	75.2%
CA 2425809 A1	HUMANIZED ANTI-LT-.BETA.-R ANTIBODIES	18/04/02	10	75.2%
US 2010 0260765 A1	TARGETED BINDING AGENTS DIRECTED TO KDR AND USES THEREOF - 035	14/10/10	139	75.2%
US 8119130 B2	Targeted binding agents directed to KDR and uses thereof—035	21/02/12	139	75.2%
JP 2010534469 A		11/11/10	139	75.2%
WO 2009 013543 A2	TARGETED BINGING AGENTS DIRECTED TO KDR AND USES THEREOF - 035	29/01/09	139	75.2%

CA 2694396 A1	TARGETED BINGING AGENTS DIRECTED TO KDR AND USES THEREOF - 035	29/01/09	139	75.2%
US 2010 0254975 A1	ALPHA-4 BETA-7 HETERODIMER SPECIFIC	07/10/10	50	73.6%
US 2012 0183561 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	19/07/12	50	73.6%
US 2012 0177662 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	12/07/12	50	73.6%
US 2013 0302354 A1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	14/11/13	50	73.6%
US 8444981 B2	Alpha-4 beta-7 heterodimer specific antagonist antibody	21/05/13	50	73.6%
US 8454961 B2	Alpha-4-beta-7 heterodimer specific antagonist antibody	04/06/13	50	73.6%
US 8454962 B2	Alpha-4-beta-7 heterodimer specific antagonist antibody	04/06/13	50	73.6%
JP 2012520679 A		10/09/12	58	73.6%
WO 2010 107752 A2	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	23/09/10	50	73.6%
KR 101391472 B1	ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	07/05/14	50	73.6%
CA 2851737 A1	ALPHA-4BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY	23/09/10	50	73.6%
US 2008 0171014 A1	Interleukin-13 binding proteins	17/07/08	88	76.6%
US 2011 0165066 A1	INTERLEUKIN-13 BINDING PROTEINS	07/07/11	88	76.6%
US 2014 0099313 A1	INTERLEUKIN-13 BINDING PROTEINS	10/04/14	88	76.6%
US 7915388 B2	Interleukin-13 binding proteins	29/03/11	88	76.6%
US 8604177 B2	Interleukin-13 binding proteins	10/12/13	88	76.6%
JP 2010502224 A		28/01/10	88	76.6%
CA 2914170 A1	INTERLEUKIN-13 BINDING PROTEINS	23/10/08	88	76.6%
WO 2014 011489 A2	MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOMIMMUNE DISEASE	16/01/14	23	75.6%
CA 2883056 A1	MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOMIMMUNE DISEASE	16/01/14	23	75.6%
US 2012 0100139 A1	CD86 Antagonist Multi-Target Binding Proteins	26/04/12	241	77.7%
JP 2012504425 A		23/02/12	287	77.7%
WO 2010 040105 A2	CD86 ANTAGONIST MULTI-TARGET BINDING PROTEINS	08/04/10	241	77.7%
CA 2739460 A1	CD86 ANTAGONIST MULTI-TARGET BINDING PROTEINS	08/04/10	241	77.7%
US 2008 0292620 A1	PRLR-Specific Antibody and Uses Thereof	27/11/08	90	73.2%
US 2011 0150760 A1	PRLR-Specific Antibody and Uses Thereof	23/06/11	90	73.2%
US 2012 0315276 A1	NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE	13/12/12	58	73.2%
US 2012 0321632 A1	NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE	20/12/12	58	73.2%
US 2013 0022606 A1	NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE	24/01/13	58	73.2%
US 2013 0129739 A1	NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE	23/05/13	58	73.2%
US 2013 0171147 A1	NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE	04/07/13	58	73.2%
US 2013 0272968 A1	NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE	17/10/13	58	73.2%
US 2014 0141003 A1	NEUTRALIZING PROLACTIN RECEPTOR ANTIBODY MAT3 AND ITS THERAPEUTIC USE	22/05/14	14	73.2%
US 7867493 B2	PRLR-specific antibody and uses thereof	11/01/11	90	73.2%
JP 2010501163 A		21/01/10	90	73.2%
WO 2008 022295 A2	PRLR-SPECIFIC ANTIBODY AND USES THEREOF	21/02/08	90	73.2%
JP 2013513559 A		22/04/13	66	73.2%
JP 2013513361 A		22/04/13	254	73.2%
JP 2013513362 A		22/04/13	66	73.2%
JP 2013513364 A		22/04/13	66	73.2%
JP 2013513365 A		22/04/13	254	73.2%
JP 2013055959 A	PRLR-SPECIFIC ANTIBODY AND USE THEREOF	28/03/13	90	73.2%
EP 2567979 A1	Use of neutralizing prolactin receptor antibodies for the treatment of hyper- and normoprolactinemic hair loss	13/03/13	58	73.2%
EP 2567978 A1	Use of neutralizing prolactin receptor antibodies for contraception	13/03/13	58	73.2%